You've been told your joints are "just hypermobile." Or maybe you've been diagnosed with rheumatoid arthritis, but something about the picture doesn't quite fit — your pain moves differently, your fatigue hits harder, your skin bruises like a peach.
Here's the thing: rheumatoid arthritis and Ehlers-Danlos syndrome show up together more often than most doctors expect. And when they do, the standard playbook falls apart The details matter here..
What Is Rheumatoid Arthritis and Ehlers-Danlos Syndrome
Let's start with the basics, because the confusion usually starts here.
Rheumatoid arthritis is an autoimmune disease. Your immune system decides your synovium — the lining of your joints — is the enemy. The result: inflammation, swelling, warmth, and eventually joint damage. It's systemic, symmetrical, and progressive if untreated Simple, but easy to overlook..
Ehlers-Danlos syndrome isn't one thing. It's a group of inherited connective tissue disorders. The most common type, hypermobile EDS (hEDS), doesn't even have a confirmed genetic marker yet. What it does have: joint hypermobility, skin that stretches too far and heals poorly, chronic pain, dysautonomia, GI issues, and a nervous system that seems stuck on high alert.
They're fundamentally different. One is acquired autoimmunity. The other is structural, genetic, lifelong.
But here's where it gets messy: they share symptoms. Morning stiffness. And fatigue. Swelling-ish sensations. Joint pain. And they can absolutely coexist.
The overlap nobody talks about
Research suggests people with hEDS have higher rates of autoimmune conditions — including RA — than the general population. The why isn't fully understood. Some theories point to chronic inflammation from microtrauma in unstable joints. So naturally, others suggest mast cell activation syndrome (common in EDS) primes the immune system for autoimmunity. Mast cells sit at the intersection of connective tissue and immune response. When they misbehave, they release histamine, tryptase, and inflammatory cytokines that can mimic or trigger autoimmune flares Most people skip this — try not to..
So no, you're not imagining it. The Venn diagram is real.
Why It Matters / Why People Care
Misdiagnosis isn't just frustrating — it changes treatment trajectories Practical, not theoretical..
If you have RA but it's missed because your hypermobility "explains everything," you lose the window for early disease-modifying therapy. Joint damage in RA is cumulative. Every month of uncontrolled inflammation is erosion you don't get back.
Flip side: if you have hEDS but get labeled seronegative RA because your inflammatory markers are mildly elevated (common in EDS from chronic subclinical inflammation), you might end up on immunosuppressants that don't address your actual problem — and carry real risks Not complicated — just consistent. But it adds up..
The stakes are higher for women. Both are underdiagnosed in women. Now, both conditions disproportionately affect women. Both get dismissed as "anxiety" or "fibromyalgia" before someone connects the dots Which is the point..
And the overlap? Now, it's not rare. A 2021 study in Rheumatology found that among patients with hypermobility spectrum disorders, roughly 1 in 8 met criteria for an inflammatory arthritis. That's not noise. That's a pattern.
How It Works: Untangling the Clinical Picture
This is where it gets practical. If you're sitting in a rheumatology office — or advocating for yourself between appointments — here's how the pieces fit together Surprisingly effective..
Clinical clues that point to RA
RA has a rhythm. The stiffness lasts more than an hour in the morning. The swelling is synovial — boggy, warm, visible. It favors wrists, MCPs, PIPs (not DIPs). It's usually symmetrical. Labs help: rheumatoid factor (RF) and anti-CCP antibodies are specific, though not perfectly sensitive. About 20-30% of RA patients are seronegative. CRP and ESR rise with flares Practical, not theoretical..
Imaging seals it. Ultrasound and MRI catch synovitis and early erosions before X-rays do.
Clinical clues that point to hEDS
hEDS doesn't show up on standard blood work. Still, diagnosis is clinical, using the 2017 criteria: generalized joint hypermobility (Beighton score), plus systemic features like skin hyperextensibility, atrophic scarring, aortic root dilation, or a positive family history. You need two of three feature domains But it adds up..
But the lived experience tells its own story: joints that sublux doing laundry. GI motility issues. Anxiety that's actually dysautonomia. Fatigue that feels like flu without fever. This leads to pain that migrates. Day to day, pOTS — heart rate spikes on standing. Allergies that aren't IgE-mediated Worth knowing..
When both are in the room
At its core, the diagnostic sweet spot — and the danger zone.
A patient with hEDS develops new, persistent, symmetrical swelling in wrists and MCPs. Morning stiffness hits 90 minutes. That's RA. Here's the thing — anti-CCP comes back positive. Treat the RA.
But — and this matters — the hEDS doesn't vanish. The joint laxity means erosions might progress differently. The dysautonomia means fatigue won't fully resolve with DMARDs. The mast cell issues mean drug reactions are more likely.
Conversely: a patient with known RA starts reporting new symptoms — frequent subluxations, stretchy skin, easy bruising, POTS. Because of that, don't chalk it up to "RA progression. " Screen for hEDS. The Beighton score takes two minutes.
The seronegative trap
Here's where clinicians get stuck. Seronegative inflammatory arthritis + hypermobility = diagnostic limbo.
Is it psoriatic arthritis? Axial spondyloarthritis? RA that hasn't seroconverted? Or is it not inflammatory at all — just mechanical pain from unstable joints, amplified by central sensitization?
Central sensitization is real. In hEDS, chronic nociceptive input from microtrauma rewires the spinal cord and brain. So pain becomes disproportionate. Widespread. Unpredictable. It looks like fibromyalgia. It feels like an autoimmune flare Practical, not theoretical..
But it doesn't respond to immunosuppression.
The differentiator: objective inflammation. On the flip side, synovitis on ultrasound. Erosions on MRI. Elevated CRP that tracks with symptoms. If those are absent — and the pain pattern is migratory, mechanical, worse with activity and better with rest (not morning stiffness) — think mechanical/central, not inflammatory.
Common Mistakes / What Most People Get Wrong
Mistake 1: Assuming hypermobility rules out RA.
It doesn't. They're independent variables. Having one doesn't immunize you against the other Small thing, real impact..
Mistake 2: Treating all joint pain in hEDS as "EDS pain."
New swelling? New symmetry? New morning stiffness? That's a new workup. Not "just your EDS acting up."
Mistake 3: Ignoring mast cell activation syndrome.
MCAS sits at the intersection. It causes flushing, GI symptoms, anaphylaxis-like episodes, and inflammatory mediator release that mimics autoimmune flares. Antihistamines and mast cell stabilizers can calm
the systemic storm, potentially resolving joint pain that was actually being driven by histamine-induced inflammation rather than synovial destruction Worth keeping that in mind..
Mistake 4: Over-reliance on the Beighton Score alone.
While the Beighton score is a useful screening tool, it is notoriously insensitive for certain phenotypes of hEDS. A patient can have significant clinical hypermobility—difficulty with functional tasks, frequent subluxations, and skin hyperextensibility—without hitting the "magic number" on a rigid scoring system. Clinical judgment must outweigh a single number.
Mistake 5: Treating the symptom, not the system.
In the overlap patient, we often focus on the "loudest" symptom. We treat the joint pain with NSAIDs, the POTS with increased salt/fluids, and the MCAS with antihistamines. But if we don't address the central sensitization or the underlying connective tissue defect, we are just playing Whac-A-Mole with a broken mallet.
The Path Forward: A Multimodal Framework
Managing the intersection of Ehlers-Danlos Syndrome and autoimmune inflammatory arthritis requires a shift from "one disease, one treatment" to a systems-based approach. It requires a clinician who is comfortable with complexity and a patient who has been taught to track their symptoms with granular precision Worth keeping that in mind..
The goal is not to find a single diagnosis that explains everything, but to map the interplay of these conditions. We must treat the inflammation where it exists (RA/SpA), stabilize the connective tissue where it fails (hEDS), and manage the systemic reactivity where it flares (MCAS/POTS) Worth knowing..
At the end of the day, the "diagnostic limbo" is not a sign of medical failure; it is a sign of clinical nuance. When we stop trying to force these overlapping conditions into mutually exclusive boxes, we move from merely managing symptoms to actually restoring function. The complexity is not the enemy—it is the map It's one of those things that adds up. Worth knowing..
